Close Menu

Danaher

Phenomenex, a privately held manufacturer of consumables for the separation sciences, will operate as a standalone business and will retain its brand. 

The GenomeWeb Index gained more than 5 percent in September, after falling more than 2 percent in August, and outperformed the Nasdaq Biotechnology Index.

Danaher expects shareholders will see returns from the acquisition in the fifth year, as post-acquisition cost savings and revenues kick in.

Trichomonas is a nonviral sexually transmitted disease caused by infection with the protozoan parasite Trichomonas vaginalis.

Danaher said that it expects the acquisition to be accretive to earnings in the fifth full year post acquisition.

Danaher Q2 net earnings fell 5 percent to $656.7 million, or $.94 per diluted share, from $695.7 million, or $.97 per diluted share, a year ago.

The company posted sales of $5.39 billion, up from $4.69 billion in the year-ago quarter, and beating the consensus Wall Street estimate of $5.33 billion.

Danaher's full-year revenues rose nearly 8 percent with its life sciences and diagnostics business its best-earning segment for both Q4 and FY2015.

Executives from Thermo Fisher Scientific, Qiagen, Danaher, Counsyl, Human Longevity, and Adaptive Biotechnologies provided business updates to conference goers.

The firm also reaffirmed is guidance for EPS for the fourth quarter of 2015 in advance of an investor meeting in New York.

Pages

A study of families explores how children transmit SARS-CoV-2, according to the Associated Press.

US Agricultural Research Service scientists have sequenced the genome of the Asian giant hornet.

According to the Economist, pooled testing for COVID-19 could help alleviate strains on testing labs.

In Science this week: MIT researchers outline approach dubbed translatable components regression to predict treatment response among IBD patients.